Literature DB >> 19210512

Neutrophils contribute to intracerebral haemorrhages after treatment with recombinant tissue plasminogen activator following cerebral ischaemia.

Sophie Gautier1, Thavarak Ouk, Olivier Petrault, Jacques Caron, Régis Bordet.   

Abstract

BACKGROUND AND
PURPOSE: Polymorphonuclear neutrophils (PMNs) contribute to the vascular damage caused by transient cerebral ischaemia. Here we have evaluated the role of PMNs in intracerebral haemorrhage (ICH) induced in a model of thrombolysis with recombinant tissue plasminogen activator (t-PA) during the acute phase of cerebral ischaemia. EXPERIMENTAL APPROACH: The middle cerebral artery (MCA) of male spontaneously hypertensive rats was occluded for 1 h followed by reperfusion and, 5 h later, infusion of thrombolytic products (generated in vitro by t-PA on autologous clots). Effects of pretreatment (before the MCA occlusion) with vinblastine (4 days before; 0.5 mg.kg(-1)), monoclonal anti-neutrophil antibody (mAbRP3; 12 h, 0.3 mg.kg(-1)) or saline on ICH, neutrophil infiltration, MCA vascular reactivity and brain infarct volume were assessed, 24 h after the beginning of reperfusion. KEY
RESULTS: Depletion of circulating neutrophils significantly reduced t-PA-induced ICH (vinblastine, 4.6 +/- 1.0; mAbRP3, 5.2 +/- 1.0 vs. saline, 10.8 +/- 2.7 haemorrhages; P < 0.05). This depletion was associated with a decrease in cerebral infiltration by neutrophils and a decrease of endothelium-dependent, vascular dysfunction in isolated MCA, induced by the ischaemia/reperfusion and t-PA treatment. Brain infarct volume was significantly decreased after vinblastine treatment (159 +/- 13 mm(3) vs. 243 +/- 16 mm(3) with saline; P < 0.01) but not after depletion with mAbRP3 (221 +/- 22 mm(3)). CONCLUSIONS AND IMPLICATIONS: Our results showed that pharmacological depletion of PMNs prevented t-PA-induced ICH, in parallel with a decrease in cerebral infiltration by PMNs and a decreased endothelial dysfunction in cerebral blood vessels.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19210512      PMCID: PMC2697703          DOI: 10.1111/j.1476-5381.2009.00068.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  44 in total

1.  Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours.

Authors:  Götz Thomalla; Jan Sobesky; Martin Köhrmann; Jochen B Fiebach; Jens Fiehler; Olivier Zaro Weber; Anna Kruetzelmann; Thomas Kucinski; Michael Rosenkranz; Joachim Röther; Peter D Schellinger
Journal:  Stroke       Date:  2007-01-04       Impact factor: 7.914

2.  Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats.

Authors:  Toshiaki Aoki; Toshihisa Sumii; Tatsuro Mori; Xiaoying Wang; Eng H Lo
Journal:  Stroke       Date:  2002-11       Impact factor: 7.914

3.  Acute tissue damage after injections of thrombin and plasmin into rat striatum.

Authors:  M Xue; M R Del Bigio
Journal:  Stroke       Date:  2001-09       Impact factor: 7.914

4.  Hemorrhagic transformation after fibrinolysis with tissue plasminogen activator: evaluation of role of hypertension with rat thromboembolic stroke model.

Authors:  E Tejima; Y Katayama; Y Suzuki; T Kano; E H Lo
Journal:  Stroke       Date:  2001-06       Impact factor: 7.914

5.  Postischemic attenuation of cerebral artery reactivity is increased in the presence of tissue plasminogen activator.

Authors:  M J Cipolla; N Lessov; W M Clark; E C Haley
Journal:  Stroke       Date:  2000-04       Impact factor: 7.914

6.  Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94.

Authors:  M Asahi; K Asahi; J C Jung; G J del Zoppo; M E Fini; E H Lo
Journal:  J Cereb Blood Flow Metab       Date:  2000-12       Impact factor: 6.200

Review 7.  The role of leukocytes following cerebral ischemia: pathogenic variable or bystander reaction to emerging infarct?

Authors:  Dwaine F Emerich; Reginald L Dean; Raymond T Bartus
Journal:  Exp Neurol       Date:  2002-01       Impact factor: 5.330

8.  Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats.

Authors:  Toshihisa Sumii; Eng H Lo
Journal:  Stroke       Date:  2002-03       Impact factor: 7.914

Review 9.  Reducing bleeding complications after thrombolytic therapy for stroke: clinical potential of metalloproteinase inhibitors and spin trap agents.

Authors:  P A Lapchak; D M Araujo
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

10.  Rapid breakdown of microvascular barriers and subsequent hemorrhagic transformation after delayed recombinant tissue plasminogen activator treatment in a rat embolic stroke model.

Authors:  Rick M Dijkhuizen; Minoru Asahi; Ona Wu; Bruce R Rosen; Eng H Lo
Journal:  Stroke       Date:  2002-08       Impact factor: 7.914

View more
  26 in total

Review 1.  Cerebral Vascular Disease and Neurovascular Injury in Ischemic Stroke.

Authors:  Xiaoming Hu; T Michael De Silva; Jun Chen; Frank M Faraci
Journal:  Circ Res       Date:  2017-02-03       Impact factor: 17.367

2.  Neutrophil Membrane-Derived Nanovesicles Alleviate Inflammation To Protect Mouse Brain Injury from Ischemic Stroke.

Authors:  Xinyue Dong; Jin Gao; Can Yang Zhang; Christopher Hayworth; Marcos Frank; Zhenjia Wang
Journal:  ACS Nano       Date:  2019-01-28       Impact factor: 15.881

3.  Neutrophil-To-Lymphocyte Ratio Predicts 3-Month Outcome of Acute Ischemic Stroke.

Authors:  Sen Qun; Yan Tang; Jing Sun; Zhaoxia Liu; Juncang Wu; Ji Zhang; Jidong Guo; Zhiqiang Xu; Dan Zhang; Zhengxu Chen; Fuyong Hu; Xingshun Xu; Wei Ge
Journal:  Neurotox Res       Date:  2017-02-08       Impact factor: 3.911

4.  Neutrophil depletion diminishes monocyte infiltration and improves functional outcome after experimental intracerebral hemorrhage.

Authors:  Lauren H Sansing; Tajie H Harris; Scott E Kasner; Christopher A Hunter; Katalin Kariko
Journal:  Acta Neurochir Suppl       Date:  2011

Review 5.  Experimental animal models and inflammatory cellular changes in cerebral ischemic and hemorrhagic stroke.

Authors:  Tao Yan; Michael Chopp; Jieli Chen
Journal:  Neurosci Bull       Date:  2015-12-02       Impact factor: 5.203

Review 6.  Hemorrhagic transformation after ischemic stroke in animals and humans.

Authors:  Glen C Jickling; DaZhi Liu; Boryana Stamova; Bradley P Ander; Xinhua Zhan; Aigang Lu; Frank R Sharp
Journal:  J Cereb Blood Flow Metab       Date:  2013-11-27       Impact factor: 6.200

7.  Effects of minocycline plus tissue plasminogen activator combination therapy after focal embolic stroke in type 1 diabetic rats.

Authors:  Xiang Fan; Eng H Lo; Xiaoying Wang
Journal:  Stroke       Date:  2013-02-19       Impact factor: 7.914

8.  Early treatment with atorvastatin exerts parenchymal and vascular protective effects in experimental cerebral ischaemia.

Authors:  C Potey; T Ouk; O Petrault; M Petrault; V Berezowski; J Salleron; R Bordet; S Gautier
Journal:  Br J Pharmacol       Date:  2015-10-06       Impact factor: 8.739

9.  Genome response to tissue plasminogen activator in experimental ischemic stroke.

Authors:  Glen C Jickling; Xinhua Zhan; Bradley P Ander; Renée J Turner; Boryana Stamova; Huichun Xu; Yingfang Tian; Dazhi Liu; Ryan R Davis; Paul A Lapchak; Frank R Sharp
Journal:  BMC Genomics       Date:  2010-04-21       Impact factor: 3.969

10.  Higher neutrophil counts before thrombolysis for cerebral ischemia predict worse outcomes.

Authors:  Ilaria Maestrini; Daniel Strbian; Sophie Gautier; Elena Haapaniemi; Solène Moulin; Tiina Sairanen; Nelly Dequatre-Ponchelle; Gerli Sibolt; Charlotte Cordonnier; Susanna Melkas; Didier Leys; Turgut Tatlisumak; Régis Bordet
Journal:  Neurology       Date:  2015-09-11       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.